- Conditions
- Chronic Hepatitis C, Hepatitis C (HCV), Hepatitis C Genotype 1
- Interventions
- ABT-450, ABT-333, ABT-267, Ribavirin, Ritonavir
- Drug
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 580 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 52 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Chronic Hepatitis C
- Interventions
- valopicitabine, pegylated interferon
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Timeline
- Started 2004
- U.S. locations
- 2
- States / cities
- Bradenton, Florida • San Antonio, Texas
- Conditions
- Autoimmune Hepatitis
- Interventions
- LCP-Tacro (tacrolimus), Azathioprine
- Drug
- Lead sponsor
- Veloxis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 8
- States / cities
- Phoenix, Arizona • Jacksonville, Florida • Chicago, Illinois + 5 more
- Conditions
- Hepatitis B, HBV
- Interventions
- Single Ascending Dose (SAD) Cohorts GS-9620, Multiple Ascending Dose (MAD) Cohorts
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Costa Mesa, California • San Diego, California + 10 more
- Conditions
- Chronic Hepatitis C
- Interventions
- ANA598 200 mg bid or placebo, ANA598 400 mg bid or placebo, ANA598 800 mg bid or placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 3
- States / cities
- St Louis, Missouri • New York, New York • San Antonio, Texas
- Conditions
- Hepatitis B
- Interventions
- INO-1800, INO-9112, Nucleos(t)ide Analogue Treatment
- Biological · Drug
- Lead sponsor
- Inovio Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 7
- States / cities
- San Diego, California • Miami, Florida • Manhasset, New York + 4 more
- Conditions
- Hepatitis, Chronic, Hepatitis C Virus
- Interventions
- Small Molecule Agent (PF-868554)
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Chronic Hepatitis C
- Interventions
- Chlorcyclizine HCl, Ribavirin
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Hepatitis C
- Interventions
- GS-9669 tablets, Placebo to Match GS-9669 tablet
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 10
- States / cities
- Los Angeles, California • DeLand, Florida • Orlando, Florida + 6 more
- Conditions
- Chronic Hepatitis B
- Interventions
- GS-7340, Tenofovir disoproxil fumarate
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 4
- States / cities
- San Diego, California • Baltimore, Maryland • Detroit, Michigan + 1 more
- Conditions
- Chronic Hepatitis C
- Interventions
- Omega DUROS device
- Drug
- Lead sponsor
- Intarcia Therapeutics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 7
- States / cities
- Los Angeles, California • San Francisco, California • St Louis, Missouri + 4 more
- Conditions
- HIV Infection, Hepatitis C Infection
- Interventions
- Nitazoxanide (NTZ), Pegylated interferon alfa-2a (PEG), Ribavirin (RBV)
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 12 more
- Conditions
- Hepatitis B, Chronic
- Interventions
- JNJ-73763989, Placebo for JNJ-73763989, JNJ-56136379, Placebo for JNJ-56136379, Nucleos(t)ide Analog (NA)
- Drug
- Lead sponsor
- Janssen Sciences Ireland UC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 471 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 8
- States / cities
- Bakersfield, California • Los Angeles, California • San Clemente, California + 5 more
- Conditions
- Hepatitis C
- Interventions
- Single Ascending Dose Cohorts GS-9620, Multiple Ascending Dose Cohorts GS-9620
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 10
- States / cities
- Little Rock, Arkansas • DeLand, Florida • Orlando, Florida + 7 more
- Conditions
- Hepatitis C
- Interventions
- ACH-0141625 (Sovaprevir), Placebo, Pegylated Interferon alpha-2a, Ribavirin
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 15
- States / cities
- Los Angeles, California • San Francisco, California • Bradenton, Florida + 11 more
- Conditions
- Hepatitis C, HCV
- Interventions
- TD-6450, Placebo
- Drug
- Lead sponsor
- Theravance Biopharma
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Chronic Hepatitis B
- Interventions
- Selgantolimod, Placebo, Hepatitis B virus (HBV) OAV Therapy
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Hepatitis D, Chronic
- Interventions
- JNJ-73763989, Placebo, Entecavir (ETV) monohydrate, Tenofovir disoproxil, Tenofovir alafenamide (TAF)
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 2
- States / cities
- Redwood City, California • Boston, Massachusetts
- Conditions
- Chronic Hepatitis C
- Interventions
- BMS-650032 or Placebo
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 5
- States / cities
- Cypress, California • Orlando, Florida • Baltimore, Maryland + 2 more
- Conditions
- Chronic Hepatitis C, Hepatitis C Virus (HCV) Infection
- Interventions
- ABT-267, Pegylated interferon (pegIFN), Ribavirin (RBV), Placebo for ABT-267
- Drug · Other
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Los Angeles, California • Orlando, Florida + 7 more
- Conditions
- HCV Infection
- Interventions
- placebo, GS-9190, Peginterferon Alfa 2a, Ribavirin
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 252 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 48
- States / cities
- Anaheim, California • Los Angeles, California • Newport Beach, California + 37 more
- Conditions
- Chronic Hepatitis C
- Interventions
- val-mCyd
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Timeline
- 2003 – 2004
- U.S. locations
- 4
- States / cities
- Pasadena, California • Boston, Massachusetts • Worcester, Massachusetts + 1 more
- Conditions
- Chronic Hepatitis C Virus Infection
- Interventions
- telaprevir, VX-222, ribavirin, peginterferon-alfa-2a
- Drug · Biological
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 19
- States / cities
- La Jolla, California • San Francisco, California • Aurora, Colorado + 16 more
- Conditions
- Cirrhosis, Liver
- Interventions
- GI262570 0.5 mg, GI262570 1.0 mg, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 40 Years to 70 Years
- Enrollment
- 265 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 58
- States / cities
- Birmingham, Alabama • Tucson, Arizona • North Little Rock, Arkansas + 45 more